Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

(2022) Delphine Planas et al.   NATURE

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2022) Elisabetta Cameroni et al.   NATURE

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

(2021) Jerzy Osipiuk et al.   Nature Communications

Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19

(2021) Kas Steuten et al.   ACS Infectious Diseases

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

(2021) Chun-Hui Zhang et al.   ACS Central Science

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

(2021) Hylemariam Mihiretie Mengist et al.   Frontiers in Chemistry

The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

(2021) Thomas P. Peacock et al.   Nature Microbiology

A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection

(2021) Fiachra Humphries et al.   Science Immunology

Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode

(2021) Gordon J. Lockbaum et al.   BIOCHEMISTRY

The origins of SARS-CoV-2: A critical review

(2021) Edward C. Holmes et al.   CELL

MPI8 is Potent against SARS‐CoV‐2 by Inhibiting Dually and Selectively the SARS‐CoV‐2 Main Protease and the Host Cathepsin L**

(2021) Xinyu R. Ma et al.   ChemMedChem

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 spike and its adaptable furin cleavage site

(2021) Gary R Whittaker   Lancet Microbe

Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L

(2021) Anneliese S. Ashhurst et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

(2021) Chunlong Ma et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

(2021) Dafydd R. Owen et al.   SCIENCE

Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells

(2021) Rina Hashimoto et al.   Molecular Therapy-Nucleic Acids

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

(2020) Zhenming Jin et al.   NATURE

Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

(2020) Tianxiao Liu et al.   PHARMACOLOGY & THERAPEUTICS

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

(2020) Wenhao Dai et al.   SCIENCE

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

(2020) Linlin Zhang et al.   SCIENCE

Introduction: A New Coronavirus Emerges, This Time Causing a Pandemic

(2020) Daniel DiMaio et al.   Annual Review of Virology

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice

(2020) Athri D. Rathnayake et al.   Science Translational Medicine

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

(2020) Robert L. Hoffman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting Proteases for Treating COVID-19

(2020) Binquan Luan et al.   JOURNAL OF PROTEOME RESEARCH

SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging

(2020) Wioletta Rut et al.   Nature Chemical Biology

Characteristics of SARS-CoV-2 and COVID-19

(2020) Ben Hu et al.   NATURE REVIEWS MICROBIOLOGY

Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches

(2020) Magda Gioia et al.   BIOCHEMICAL PHARMACOLOGY

A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**

(2020) Kai S. Yang et al.   ChemMedChem

Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection

(2020) Pranesh Padmanabhan et al.   PLoS Computational Biology

Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics

(2020) Caio P. Gomes et al.   Frontiers in Cellular and Infection Microbiology

Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?

(2012) Jasper F.W. Chan et al.   JOURNAL OF INFECTION

Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide

(2008) B. J. Bosch et al.   JOURNAL OF VIROLOGY